Neuphoria Therapeutics Beat Consensus Estimates

Neuphoria Therapeutics (NEUP) reported a loss of $0.13 per share on revenue of $1.17 million for the fiscal fourth quarter ended June 2026. The consensus estimate was a loss of $0.56 per share. The company beat consensus estimates by 76.79% while revenue grew 8,930.77% on a year-over-year basis.

Bionomics Limited is a clinical-stage biopharmaceutical developing novel, allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system disorders. Bionomics Limited is based in ADELAIDE, Australia.